Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin)
- PMID: 9741353
- PMCID: PMC1364217
- DOI: 10.1046/j.1365-2567.1998.00495.x
Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin)
Abstract
The mode of action of intravenous immunoglobulins (IVIG) in autoimmune and immunoregulatory disorders is still poorly understood. In vitro, direct effects of IVIG on cytokine release and on cytokine receptors have been described, as well as naturally occurring, neutralizing anticytokine antibodies. The aim of our study was to investigate whether the enrichment in IgM and IgA would have any impact on the in vitro immunomodilatory capacity of IVIG. The preparation tested (Pentaglobin) contains 76% IgG and 12% IgM and IgA, respectively. We could demonstrate a significant inhibition of alloantigen-induced proliferation in the mixed lymphocyte reaction (MLR) even at a Pentaglobin concentration of 1.0 mg/ml. About 10-fold higher concentrations of standard 7S IVIG containing only trace amounts of IgM and IgA were necessary to achieve equivalent suppression of the alloimmune response. Similarly, phytohaemagglutinin (PHA)-induced lymphocyte proliferation was more effectively inhibited by Pentaglobin than by standard 7S IVIG. Cytokine analyses in culture supernatants of MLR provide evidence that Pentaglobin not only modulates interleukin-2 (IL-2), which has already been observed with standard 7S IVIG, but, moreover, modulates interferon-gamma production with a subsequent impact on monocyte-derived tumour necrosis factor-alpha and IL-6 release. Based on these results we conclude that in vitro the IgM- and IgA-enriched Pentaglobin has a more potent immunomodulatory capacity than conventionally used standard 7S IVIG.
Similar articles
-
A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.Immunology. 1997 Feb;90(2):212-8. doi: 10.1046/j.1365-2567.1997.d01-2148.x. Immunology. 1997. PMID: 9135549 Free PMC article.
-
Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins.Transplantation. 1996 Nov 15;62(9):1292-6. doi: 10.1097/00007890-199611150-00020. Transplantation. 1996. PMID: 8932274
-
Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.Sci Rep. 2021 Jun 21;11(1):12926. doi: 10.1038/s41598-021-92412-8. Sci Rep. 2021. PMID: 34155276 Free PMC article.
-
Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis.J Intern Med. 2006 Dec;260(6):509-16. doi: 10.1111/j.1365-2796.2006.01726.x. J Intern Med. 2006. PMID: 17116001 Review.
-
Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis.Ann Intensive Care. 2020 Oct 7;10(1):132. doi: 10.1186/s13613-020-00740-1. Ann Intensive Care. 2020. PMID: 33026597 Free PMC article. Review.
Cited by
-
Sepsis-Pathophysiology and Therapeutic Concepts.Front Med (Lausanne). 2021 May 14;8:628302. doi: 10.3389/fmed.2021.628302. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34055825 Free PMC article. Review.
-
The use of high-dose immunoglobulin M-enriched human immunoglobulin in dogs with immune-mediated hemolytic anemia.J Vet Intern Med. 2022 Jan;36(1):78-85. doi: 10.1111/jvim.16315. Epub 2021 Nov 15. J Vet Intern Med. 2022. PMID: 34779044 Free PMC article.
-
Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study.Crit Care. 2022 Jul 7;26(1):204. doi: 10.1186/s13054-022-04059-0. Crit Care. 2022. PMID: 35799196 Free PMC article.
-
A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases.Front Immunol. 2023 Mar 27;14:1127339. doi: 10.3389/fimmu.2023.1127339. eCollection 2023. Front Immunol. 2023. PMID: 37051237 Free PMC article. Review.
-
Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.Int J Mol Sci. 2020 Aug 3;21(15):5543. doi: 10.3390/ijms21155543. Int J Mol Sci. 2020. PMID: 32756325 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous